nodes	percent_of_prediction	percent_of_DWPC	metapath
Chlorpromazine—ALB—Vismodegib—skin cancer	0.0883	0.132	CbGbCtD
Chlorpromazine—CYP1A2—Imiquimod—skin cancer	0.0762	0.114	CbGbCtD
Chlorpromazine—ALB—Vemurafenib—skin cancer	0.0698	0.105	CbGbCtD
Chlorpromazine—CYP2E1—Dacarbazine—skin cancer	0.0554	0.0829	CbGbCtD
Chlorpromazine—ABCB1—Vismodegib—skin cancer	0.0462	0.0692	CbGbCtD
Chlorpromazine—CYP1A2—Vemurafenib—skin cancer	0.0418	0.0625	CbGbCtD
Chlorpromazine—CYP3A4—Imiquimod—skin cancer	0.0399	0.0598	CbGbCtD
Chlorpromazine—CYP3A4—Temozolomide—skin cancer	0.0399	0.0598	CbGbCtD
Chlorpromazine—CYP2D6—Vemurafenib—skin cancer	0.0344	0.0515	CbGbCtD
Chlorpromazine—CYP1A2—Dacarbazine—skin cancer	0.032	0.0479	CbGbCtD
Chlorpromazine—ALB—Fluorouracil—skin cancer	0.0314	0.047	CbGbCtD
Chlorpromazine—CYP3A4—Vismodegib—skin cancer	0.0277	0.0414	CbGbCtD
Chlorpromazine—ABCB1—Dactinomycin—skin cancer	0.0243	0.0363	CbGbCtD
Chlorpromazine—CYP3A4—Vemurafenib—skin cancer	0.0219	0.0328	CbGbCtD
Chlorpromazine—CYP1A2—Fluorouracil—skin cancer	0.0188	0.0281	CbGbCtD
Chlorpromazine—DRD5—eyelid—skin cancer	0.0143	0.119	CbGeAlD
Chlorpromazine—ABCB1—Docetaxel—skin cancer	0.0125	0.0188	CbGbCtD
Chlorpromazine—CYP3A4—Docetaxel—skin cancer	0.00751	0.0112	CbGbCtD
Chlorpromazine—Edema cerebral—Temozolomide—skin cancer	0.00692	0.0677	CcSEcCtD
Chlorpromazine—CHRM3—muscle of abdomen—skin cancer	0.00615	0.051	CbGeAlD
Chlorpromazine—HRH1—nose—skin cancer	0.00475	0.0394	CbGeAlD
Chlorpromazine—Amenorrhoea—Vismodegib—skin cancer	0.00386	0.0378	CcSEcCtD
Chlorpromazine—Brain oedema—Temozolomide—skin cancer	0.00375	0.0367	CcSEcCtD
Chlorpromazine—Pigmentation disorder—Temozolomide—skin cancer	0.00321	0.0314	CcSEcCtD
Chlorpromazine—CALM2—ear—skin cancer	0.00298	0.0247	CbGeAlD
Chlorpromazine—CALM1—ear—skin cancer	0.00297	0.0246	CbGeAlD
Chlorpromazine—DRD1—nerve—skin cancer	0.00292	0.0242	CbGeAlD
Chlorpromazine—Parkinsonism—Fluorouracil—skin cancer	0.00217	0.0212	CcSEcCtD
Chlorpromazine—SMPD1—connective tissue—skin cancer	0.00207	0.0172	CbGeAlD
Chlorpromazine—Sudden death—Fluorouracil—skin cancer	0.00193	0.0189	CcSEcCtD
Chlorpromazine—CALM2—nerve—skin cancer	0.00188	0.0155	CbGeAlD
Chlorpromazine—SMPD1—skin of body—skin cancer	0.00187	0.0155	CbGeAlD
Chlorpromazine—HTR2A—hindlimb—skin cancer	0.00187	0.0155	CbGeAlD
Chlorpromazine—CALM1—nerve—skin cancer	0.00187	0.0155	CbGeAlD
Chlorpromazine—HTR7—nerve—skin cancer	0.00182	0.0151	CbGeAlD
Chlorpromazine—Photosensitivity—Vemurafenib—skin cancer	0.00173	0.0169	CcSEcCtD
Chlorpromazine—DRD2—nerve—skin cancer	0.00172	0.0143	CbGeAlD
Chlorpromazine—HTR2A—appendage—skin cancer	0.0016	0.0133	CbGeAlD
Chlorpromazine—CALM2—endothelium—skin cancer	0.0016	0.0132	CbGeAlD
Chlorpromazine—CALM1—endothelium—skin cancer	0.00159	0.0132	CbGeAlD
Chlorpromazine—CALM2—hair follicle—skin cancer	0.00157	0.013	CbGeAlD
Chlorpromazine—HTR7—endothelium—skin cancer	0.00155	0.0129	CbGeAlD
Chlorpromazine—SMPD1—lymphoid tissue—skin cancer	0.00152	0.0126	CbGeAlD
Chlorpromazine—CALM2—blood vessel—skin cancer	0.00147	0.0122	CbGeAlD
Chlorpromazine—CALM1—blood vessel—skin cancer	0.00147	0.0122	CbGeAlD
Chlorpromazine—SMPD1—female reproductive system—skin cancer	0.00146	0.0121	CbGeAlD
Chlorpromazine—Menorrhagia—Temozolomide—skin cancer	0.00145	0.0142	CcSEcCtD
Chlorpromazine—HTR7—blood vessel—skin cancer	0.00143	0.0119	CbGeAlD
Chlorpromazine—Muscle spasms—Vismodegib—skin cancer	0.00142	0.0139	CcSEcCtD
Chlorpromazine—Nasal congestion—Imiquimod—skin cancer	0.00142	0.0139	CcSEcCtD
Chlorpromazine—Extrapyramidal disorder—Temozolomide—skin cancer	0.00142	0.0139	CcSEcCtD
Chlorpromazine—Dermatitis exfoliative—Imiquimod—skin cancer	0.00137	0.0134	CcSEcCtD
Chlorpromazine—CALM3—nipple—skin cancer	0.00136	0.0112	CbGeAlD
Chlorpromazine—Eosinophilia—Vemurafenib—skin cancer	0.0013	0.0127	CcSEcCtD
Chlorpromazine—Endocrine disorder—Temozolomide—skin cancer	0.00129	0.0126	CcSEcCtD
Chlorpromazine—Systemic lupus erythematosus—Docetaxel—skin cancer	0.00129	0.0126	CcSEcCtD
Chlorpromazine—Urinary retention—Imiquimod—skin cancer	0.00123	0.0121	CcSEcCtD
Chlorpromazine—SMPD1—head—skin cancer	0.00122	0.0101	CbGeAlD
Chlorpromazine—Amenorrhoea—Temozolomide—skin cancer	0.00122	0.0119	CcSEcCtD
Chlorpromazine—Photosensitivity reaction—Vemurafenib—skin cancer	0.0012	0.0117	CcSEcCtD
Chlorpromazine—HTR2A—nerve—skin cancer	0.00114	0.00943	CbGeAlD
Chlorpromazine—DRD5—lymphoid tissue—skin cancer	0.00112	0.00932	CbGeAlD
Chlorpromazine—Influenza—Imiquimod—skin cancer	0.00112	0.011	CcSEcCtD
Chlorpromazine—Aplastic anaemia—Dactinomycin—skin cancer	0.00111	0.0109	CcSEcCtD
Chlorpromazine—Gait disturbance—Temozolomide—skin cancer	0.0011	0.0107	CcSEcCtD
Chlorpromazine—DRD5—female reproductive system—skin cancer	0.00108	0.00899	CbGeAlD
Chlorpromazine—CALM2—nipple—skin cancer	0.00107	0.00883	CbGeAlD
Chlorpromazine—Pancytopenia—Imiquimod—skin cancer	0.00106	0.0104	CcSEcCtD
Chlorpromazine—CALM1—nipple—skin cancer	0.00106	0.00878	CbGeAlD
Chlorpromazine—CALM2—neck—skin cancer	0.00105	0.00873	CbGeAlD
Chlorpromazine—CALM1—neck—skin cancer	0.00105	0.00869	CbGeAlD
Chlorpromazine—Oedema peripheral—Vemurafenib—skin cancer	0.00104	0.0101	CcSEcCtD
Chlorpromazine—Constipation—Vismodegib—skin cancer	0.00103	0.0101	CcSEcCtD
Chlorpromazine—Erectile dysfunction—Imiquimod—skin cancer	0.00103	0.0101	CcSEcCtD
Chlorpromazine—HTR7—neck—skin cancer	0.00102	0.00849	CbGeAlD
Chlorpromazine—Photosensitivity reaction—Imiquimod—skin cancer	0.00102	0.01	CcSEcCtD
Chlorpromazine—Aplastic anaemia—Temozolomide—skin cancer	0.00101	0.00984	CcSEcCtD
Chlorpromazine—Throat sore—Docetaxel—skin cancer	0.000988	0.00967	CcSEcCtD
Chlorpromazine—Oropharyngeal discomfort—Docetaxel—skin cancer	0.000979	0.00958	CcSEcCtD
Chlorpromazine—Dermatitis contact—Fluorouracil—skin cancer	0.000975	0.00954	CcSEcCtD
Chlorpromazine—HTR2A—endothelium—skin cancer	0.000969	0.00803	CbGeAlD
Chlorpromazine—DRD3—head—skin cancer	0.000967	0.00801	CbGeAlD
Chlorpromazine—KCNH2—nipple—skin cancer	0.000965	0.00799	CbGeAlD
Chlorpromazine—HTR6—head—skin cancer	0.000931	0.00771	CbGeAlD
Chlorpromazine—DRD5—head—skin cancer	0.000906	0.00751	CbGeAlD
Chlorpromazine—HTR2A—blood vessel—skin cancer	0.000893	0.0074	CbGeAlD
Chlorpromazine—BCHE—nipple—skin cancer	0.000888	0.00736	CbGeAlD
Chlorpromazine—Visual impairment—Imiquimod—skin cancer	0.000864	0.00846	CcSEcCtD
Chlorpromazine—SMPD1—lymph node—skin cancer	0.000856	0.00709	CbGeAlD
Chlorpromazine—Nasal congestion—Temozolomide—skin cancer	0.000853	0.00835	CcSEcCtD
Chlorpromazine—CYP1A2—nipple—skin cancer	0.000826	0.00684	CbGeAlD
Chlorpromazine—Dermatitis exfoliative—Temozolomide—skin cancer	0.000823	0.00806	CcSEcCtD
Chlorpromazine—Photosensitivity—Fluorouracil—skin cancer	0.000815	0.00798	CcSEcCtD
Chlorpromazine—Amenorrhoea—Docetaxel—skin cancer	0.00081	0.00793	CcSEcCtD
Chlorpromazine—Cough—Vemurafenib—skin cancer	0.000799	0.00782	CcSEcCtD
Chlorpromazine—CALM3—mammalian vulva—skin cancer	0.000792	0.00656	CbGeAlD
Chlorpromazine—Oropharyngeal pain—Docetaxel—skin cancer	0.000783	0.00766	CcSEcCtD
Chlorpromazine—HTR2B—skin of body—skin cancer	0.000774	0.00642	CbGeAlD
Chlorpromazine—HRH1—nipple—skin cancer	0.000773	0.00641	CbGeAlD
Chlorpromazine—ADRA2A—nipple—skin cancer	0.00076	0.00629	CbGeAlD
Chlorpromazine—Pancytopenia—Bleomycin—skin cancer	0.000756	0.0074	CcSEcCtD
Chlorpromazine—CALM2—connective tissue—skin cancer	0.000755	0.00626	CbGeAlD
Chlorpromazine—CALM1—connective tissue—skin cancer	0.000752	0.00623	CbGeAlD
Chlorpromazine—Anaphylactic shock—Vemurafenib—skin cancer	0.000747	0.00731	CcSEcCtD
Chlorpromazine—ADRA1B—head—skin cancer	0.000743	0.00616	CbGeAlD
Chlorpromazine—Dysphagia—Dactinomycin—skin cancer	0.000743	0.00727	CcSEcCtD
Chlorpromazine—Infection—Vemurafenib—skin cancer	0.000742	0.00727	CcSEcCtD
Chlorpromazine—HTR7—connective tissue—skin cancer	0.000734	0.00609	CbGeAlD
Chlorpromazine—CALM2—epithelium—skin cancer	0.000717	0.00594	CbGeAlD
Chlorpromazine—CALM1—epithelium—skin cancer	0.000714	0.00591	CbGeAlD
Chlorpromazine—Angioedema—Imiquimod—skin cancer	0.000713	0.00698	CcSEcCtD
Chlorpromazine—Pancytopenia—Dactinomycin—skin cancer	0.000705	0.0069	CcSEcCtD
Chlorpromazine—Syncope—Imiquimod—skin cancer	0.0007	0.00685	CcSEcCtD
Chlorpromazine—Hypotension—Vemurafenib—skin cancer	0.000698	0.00683	CcSEcCtD
Chlorpromazine—HTR7—epithelium—skin cancer	0.000697	0.00578	CbGeAlD
Chlorpromazine—DRD1—head—skin cancer	0.000693	0.00574	CbGeAlD
Chlorpromazine—Loss of consciousness—Imiquimod—skin cancer	0.000686	0.00672	CcSEcCtD
Chlorpromazine—CALM2—skin of body—skin cancer	0.000682	0.00565	CbGeAlD
Chlorpromazine—Cough—Imiquimod—skin cancer	0.000681	0.00667	CcSEcCtD
Chlorpromazine—Cardiac arrest—Fluorouracil—skin cancer	0.000681	0.00666	CcSEcCtD
Chlorpromazine—CALM1—skin of body—skin cancer	0.000679	0.00563	CbGeAlD
Chlorpromazine—Convulsion—Imiquimod—skin cancer	0.000677	0.00662	CcSEcCtD
Chlorpromazine—ADRA1A—epithelium—skin cancer	0.000673	0.00557	CbGeAlD
Chlorpromazine—Dysphagia—Temozolomide—skin cancer	0.000672	0.00657	CcSEcCtD
Chlorpromazine—Dry mouth—Imiquimod—skin cancer	0.00065	0.00636	CcSEcCtD
Chlorpromazine—HTR2C—female reproductive system—skin cancer	0.000644	0.00534	CbGeAlD
Chlorpromazine—HTR2A—neck—skin cancer	0.000639	0.0053	CbGeAlD
Chlorpromazine—Constipation—Vemurafenib—skin cancer	0.000639	0.00625	CcSEcCtD
Chlorpromazine—Pancytopenia—Temozolomide—skin cancer	0.000638	0.00624	CcSEcCtD
Chlorpromazine—Infection—Imiquimod—skin cancer	0.000633	0.0062	CcSEcCtD
Chlorpromazine—Shock—Imiquimod—skin cancer	0.000627	0.00614	CcSEcCtD
Chlorpromazine—CALM2—mammalian vulva—skin cancer	0.000622	0.00515	CbGeAlD
Chlorpromazine—Tachycardia—Imiquimod—skin cancer	0.000622	0.00609	CcSEcCtD
Chlorpromazine—CALM1—mammalian vulva—skin cancer	0.000619	0.00513	CbGeAlD
Chlorpromazine—Dysphagia—Fluorouracil—skin cancer	0.000619	0.00606	CcSEcCtD
Chlorpromazine—Erectile dysfunction—Temozolomide—skin cancer	0.000619	0.00605	CcSEcCtD
Chlorpromazine—Agranulocytosis—Dactinomycin—skin cancer	0.000618	0.00605	CcSEcCtD
Chlorpromazine—Photosensitivity reaction—Temozolomide—skin cancer	0.000613	0.006	CcSEcCtD
Chlorpromazine—Eosinophilia—Fluorouracil—skin cancer	0.000613	0.006	CcSEcCtD
Chlorpromazine—CHRM1—female reproductive system—skin cancer	0.000608	0.00504	CbGeAlD
Chlorpromazine—Hyperglycaemia—Temozolomide—skin cancer	0.000606	0.00593	CcSEcCtD
Chlorpromazine—HTR2B—female reproductive system—skin cancer	0.000605	0.00501	CbGeAlD
Chlorpromazine—Body temperature increased—Vemurafenib—skin cancer	0.000591	0.00578	CcSEcCtD
Chlorpromazine—Pancytopenia—Fluorouracil—skin cancer	0.000588	0.00575	CcSEcCtD
Chlorpromazine—ABCB1—blood vessel—skin cancer	0.000585	0.00485	CbGeAlD
Chlorpromazine—Insomnia—Imiquimod—skin cancer	0.000576	0.00564	CcSEcCtD
Chlorpromazine—BCHE—skin of body—skin cancer	0.000569	0.00471	CbGeAlD
Chlorpromazine—Dyspnoea—Imiquimod—skin cancer	0.000568	0.00556	CcSEcCtD
Chlorpromazine—Somnolence—Imiquimod—skin cancer	0.000567	0.00554	CcSEcCtD
Chlorpromazine—Photosensitivity reaction—Fluorouracil—skin cancer	0.000565	0.00553	CcSEcCtD
Chlorpromazine—CHRM2—head—skin cancer	0.000558	0.00463	CbGeAlD
Chlorpromazine—CALM2—lymphoid tissue—skin cancer	0.000552	0.00458	CbGeAlD
Chlorpromazine—Hypersensitivity—Vemurafenib—skin cancer	0.000551	0.00539	CcSEcCtD
Chlorpromazine—CALM1—lymphoid tissue—skin cancer	0.00055	0.00456	CbGeAlD
Chlorpromazine—HRH1—connective tissue—skin cancer	0.000548	0.00454	CbGeAlD
Chlorpromazine—SLC22A1—head—skin cancer	0.000548	0.00454	CbGeAlD
Chlorpromazine—CHRM3—female reproductive system—skin cancer	0.000544	0.00451	CbGeAlD
Chlorpromazine—ADRA2A—connective tissue—skin cancer	0.000539	0.00446	CbGeAlD
Chlorpromazine—HTR2C—head—skin cancer	0.000538	0.00446	CbGeAlD
Chlorpromazine—CALM2—female reproductive system—skin cancer	0.000533	0.00441	CbGeAlD
Chlorpromazine—CALM1—female reproductive system—skin cancer	0.00053	0.00439	CbGeAlD
Chlorpromazine—Oedema peripheral—Temozolomide—skin cancer	0.00053	0.00518	CcSEcCtD
Chlorpromazine—HRH1—epithelium—skin cancer	0.000521	0.00431	CbGeAlD
Chlorpromazine—BCHE—mammalian vulva—skin cancer	0.000519	0.0043	CbGeAlD
Chlorpromazine—Visual impairment—Temozolomide—skin cancer	0.000518	0.00507	CcSEcCtD
Chlorpromazine—ADRA1A—lymphoid tissue—skin cancer	0.000518	0.00429	CbGeAlD
Chlorpromazine—HTR7—female reproductive system—skin cancer	0.000518	0.00429	CbGeAlD
Chlorpromazine—Agranulocytosis—Fluorouracil—skin cancer	0.000515	0.00504	CcSEcCtD
Chlorpromazine—CHRM1—head—skin cancer	0.000508	0.00421	CbGeAlD
Chlorpromazine—HTR2B—head—skin cancer	0.000505	0.00419	CbGeAlD
Chlorpromazine—Body temperature increased—Imiquimod—skin cancer	0.000504	0.00493	CcSEcCtD
Chlorpromazine—Leukopenia—Bleomycin—skin cancer	0.000497	0.00486	CcSEcCtD
Chlorpromazine—Dizziness—Vemurafenib—skin cancer	0.000494	0.00484	CcSEcCtD
Chlorpromazine—Cough—Bleomycin—skin cancer	0.000484	0.00474	CcSEcCtD
Chlorpromazine—KCNH2—female reproductive system—skin cancer	0.000483	0.004	CbGeAlD
Chlorpromazine—Orthostatic hypotension—Docetaxel—skin cancer	0.000472	0.00462	CcSEcCtD
Chlorpromazine—Hypersensitivity—Imiquimod—skin cancer	0.00047	0.00459	CcSEcCtD
Chlorpromazine—Leukopenia—Dactinomycin—skin cancer	0.000463	0.00453	CcSEcCtD
Chlorpromazine—HTR2A—connective tissue—skin cancer	0.000458	0.0038	CbGeAlD
Chlorpromazine—CHRM3—head—skin cancer	0.000455	0.00377	CbGeAlD
Chlorpromazine—HTR1A—head—skin cancer	0.000453	0.00375	CbGeAlD
Chlorpromazine—Anaphylactic shock—Bleomycin—skin cancer	0.000453	0.00443	CcSEcCtD
Chlorpromazine—HRH1—mammalian vulva—skin cancer	0.000452	0.00374	CbGeAlD
Chlorpromazine—Infection—Bleomycin—skin cancer	0.00045	0.0044	CcSEcCtD
Chlorpromazine—Dysphagia—Docetaxel—skin cancer	0.000447	0.00437	CcSEcCtD
Chlorpromazine—CALM2—head—skin cancer	0.000445	0.00369	CbGeAlD
Chlorpromazine—BCHE—female reproductive system—skin cancer	0.000444	0.00368	CbGeAlD
Chlorpromazine—ADRA2A—mammalian vulva—skin cancer	0.000444	0.00368	CbGeAlD
Chlorpromazine—CALM1—head—skin cancer	0.000443	0.00367	CbGeAlD
Chlorpromazine—Tremor—Temozolomide—skin cancer	0.000438	0.00429	CcSEcCtD
Chlorpromazine—HTR2A—epithelium—skin cancer	0.000435	0.0036	CbGeAlD
Chlorpromazine—HTR7—head—skin cancer	0.000433	0.00359	CbGeAlD
Chlorpromazine—Angioedema—Temozolomide—skin cancer	0.000428	0.00418	CcSEcCtD
Chlorpromazine—Pancytopenia—Docetaxel—skin cancer	0.000424	0.00415	CcSEcCtD
Chlorpromazine—Hypotension—Bleomycin—skin cancer	0.000423	0.00414	CcSEcCtD
Chlorpromazine—Dizziness—Imiquimod—skin cancer	0.000421	0.00412	CcSEcCtD
Chlorpromazine—Infection—Dactinomycin—skin cancer	0.000419	0.00411	CcSEcCtD
Chlorpromazine—Leukopenia—Temozolomide—skin cancer	0.000419	0.0041	CcSEcCtD
Chlorpromazine—ADRA1A—head—skin cancer	0.000417	0.00346	CbGeAlD
Chlorpromazine—DRD2—head—skin cancer	0.000409	0.00339	CbGeAlD
Chlorpromazine—Cough—Temozolomide—skin cancer	0.000408	0.004	CcSEcCtD
Chlorpromazine—Convulsion—Temozolomide—skin cancer	0.000405	0.00397	CcSEcCtD
Chlorpromazine—Dyspnoea—Bleomycin—skin cancer	0.000404	0.00395	CcSEcCtD
Chlorpromazine—KCNH2—head—skin cancer	0.000403	0.00334	CbGeAlD
Chlorpromazine—CALM3—lymph node—skin cancer	0.000397	0.00329	CbGeAlD
Chlorpromazine—Dry mouth—Temozolomide—skin cancer	0.00039	0.00381	CcSEcCtD
Chlorpromazine—Jaundice—Docetaxel—skin cancer	0.000388	0.0038	CcSEcCtD
Chlorpromazine—HRH1—female reproductive system—skin cancer	0.000387	0.0032	CbGeAlD
Chlorpromazine—Leukopenia—Fluorouracil—skin cancer	0.000386	0.00378	CcSEcCtD
Chlorpromazine—CYP2E1—lymphoid tissue—skin cancer	0.000385	0.00319	CbGeAlD
Chlorpromazine—Anaphylactic shock—Temozolomide—skin cancer	0.000382	0.00374	CcSEcCtD
Chlorpromazine—ADRA2A—female reproductive system—skin cancer	0.00038	0.00315	CbGeAlD
Chlorpromazine—Infection—Temozolomide—skin cancer	0.000379	0.00371	CcSEcCtD
Chlorpromazine—Convulsion—Fluorouracil—skin cancer	0.000374	0.00366	CcSEcCtD
Chlorpromazine—CYP2E1—female reproductive system—skin cancer	0.000372	0.00308	CbGeAlD
Chlorpromazine—Agranulocytosis—Docetaxel—skin cancer	0.000372	0.00364	CcSEcCtD
Chlorpromazine—BCHE—head—skin cancer	0.000371	0.00307	CbGeAlD
Chlorpromazine—ALB—lymph node—skin cancer	0.000367	0.00305	CbGeAlD
Chlorpromazine—Body temperature increased—Bleomycin—skin cancer	0.000358	0.0035	CcSEcCtD
Chlorpromazine—HTR2B—lymph node—skin cancer	0.000354	0.00293	CbGeAlD
Chlorpromazine—Oedema peripheral—Docetaxel—skin cancer	0.000352	0.00345	CcSEcCtD
Chlorpromazine—Anaphylactic shock—Fluorouracil—skin cancer	0.000352	0.00344	CcSEcCtD
Chlorpromazine—Infection—Fluorouracil—skin cancer	0.00035	0.00342	CcSEcCtD
Chlorpromazine—Insomnia—Temozolomide—skin cancer	0.000345	0.00338	CcSEcCtD
Chlorpromazine—Visual impairment—Docetaxel—skin cancer	0.000344	0.00337	CcSEcCtD
Chlorpromazine—Tachycardia—Fluorouracil—skin cancer	0.000343	0.00336	CcSEcCtD
Chlorpromazine—Dyspnoea—Temozolomide—skin cancer	0.00034	0.00333	CcSEcCtD
Chlorpromazine—Somnolence—Temozolomide—skin cancer	0.00034	0.00332	CcSEcCtD
Chlorpromazine—Body temperature increased—Dactinomycin—skin cancer	0.000334	0.00327	CcSEcCtD
Chlorpromazine—Hypersensitivity—Bleomycin—skin cancer	0.000334	0.00326	CcSEcCtD
Chlorpromazine—Hypotension—Fluorouracil—skin cancer	0.000329	0.00322	CcSEcCtD
Chlorpromazine—Constipation—Temozolomide—skin cancer	0.000327	0.0032	CcSEcCtD
Chlorpromazine—HRH1—head—skin cancer	0.000323	0.00268	CbGeAlD
Chlorpromazine—HTR2A—female reproductive system—skin cancer	0.000323	0.00268	CbGeAlD
Chlorpromazine—Insomnia—Fluorouracil—skin cancer	0.000318	0.00311	CcSEcCtD
Chlorpromazine—ADRA2A—head—skin cancer	0.000317	0.00263	CbGeAlD
Chlorpromazine—Dyspnoea—Fluorouracil—skin cancer	0.000314	0.00307	CcSEcCtD
Chlorpromazine—Somnolence—Fluorouracil—skin cancer	0.000313	0.00306	CcSEcCtD
Chlorpromazine—CALM2—lymph node—skin cancer	0.000312	0.00258	CbGeAlD
Chlorpromazine—Hypersensitivity—Dactinomycin—skin cancer	0.000311	0.00304	CcSEcCtD
Chlorpromazine—CYP2E1—head—skin cancer	0.00031	0.00257	CbGeAlD
Chlorpromazine—CALM1—lymph node—skin cancer	0.00031	0.00257	CbGeAlD
Chlorpromazine—Body temperature increased—Temozolomide—skin cancer	0.000302	0.00295	CcSEcCtD
Chlorpromazine—Muscle spasms—Docetaxel—skin cancer	0.000299	0.00293	CcSEcCtD
Chlorpromazine—CYP3A4—female reproductive system—skin cancer	0.000299	0.00248	CbGeAlD
Chlorpromazine—CYP2D6—female reproductive system—skin cancer	0.000294	0.00244	CbGeAlD
Chlorpromazine—ABCB1—epithelium—skin cancer	0.000285	0.00236	CbGeAlD
Chlorpromazine—KCNH2—lymph node—skin cancer	0.000282	0.00234	CbGeAlD
Chlorpromazine—Hypersensitivity—Temozolomide—skin cancer	0.000281	0.00275	CcSEcCtD
Chlorpromazine—Syncope—Docetaxel—skin cancer	0.000279	0.00273	CcSEcCtD
Chlorpromazine—Leukopenia—Docetaxel—skin cancer	0.000279	0.00273	CcSEcCtD
Chlorpromazine—Body temperature increased—Fluorouracil—skin cancer	0.000278	0.00272	CcSEcCtD
Chlorpromazine—Loss of consciousness—Docetaxel—skin cancer	0.000274	0.00268	CcSEcCtD
Chlorpromazine—Cough—Docetaxel—skin cancer	0.000272	0.00266	CcSEcCtD
Chlorpromazine—HTR2A—head—skin cancer	0.00027	0.00224	CbGeAlD
Chlorpromazine—Convulsion—Docetaxel—skin cancer	0.00027	0.00264	CcSEcCtD
Chlorpromazine—BCHE—lymph node—skin cancer	0.00026	0.00215	CbGeAlD
Chlorpromazine—Hypersensitivity—Fluorouracil—skin cancer	0.000259	0.00254	CcSEcCtD
Chlorpromazine—Dry mouth—Docetaxel—skin cancer	0.000259	0.00254	CcSEcCtD
Chlorpromazine—Anaphylactic shock—Docetaxel—skin cancer	0.000254	0.00249	CcSEcCtD
Chlorpromazine—Dizziness—Temozolomide—skin cancer	0.000253	0.00247	CcSEcCtD
Chlorpromazine—Infection—Docetaxel—skin cancer	0.000252	0.00247	CcSEcCtD
Chlorpromazine—Shock—Docetaxel—skin cancer	0.00025	0.00245	CcSEcCtD
Chlorpromazine—Tachycardia—Docetaxel—skin cancer	0.000248	0.00243	CcSEcCtD
Chlorpromazine—ABCB1—mammalian vulva—skin cancer	0.000247	0.00205	CbGeAlD
Chlorpromazine—CYP2D6—head—skin cancer	0.000246	0.00204	CbGeAlD
Chlorpromazine—Hypotension—Docetaxel—skin cancer	0.000237	0.00232	CcSEcCtD
Chlorpromazine—Dizziness—Fluorouracil—skin cancer	0.000233	0.00228	CcSEcCtD
Chlorpromazine—Insomnia—Docetaxel—skin cancer	0.00023	0.00225	CcSEcCtD
Chlorpromazine—Dyspnoea—Docetaxel—skin cancer	0.000226	0.00222	CcSEcCtD
Chlorpromazine—HRH1—lymph node—skin cancer	0.000226	0.00187	CbGeAlD
Chlorpromazine—Somnolence—Docetaxel—skin cancer	0.000226	0.00221	CcSEcCtD
Chlorpromazine—ADRA2A—lymph node—skin cancer	0.000222	0.00184	CbGeAlD
Chlorpromazine—ABCB1—lymphoid tissue—skin cancer	0.000219	0.00182	CbGeAlD
Chlorpromazine—Constipation—Docetaxel—skin cancer	0.000217	0.00213	CcSEcCtD
Chlorpromazine—ABCB1—female reproductive system—skin cancer	0.000212	0.00175	CbGeAlD
Chlorpromazine—Body temperature increased—Docetaxel—skin cancer	0.000201	0.00196	CcSEcCtD
Chlorpromazine—Hypersensitivity—Docetaxel—skin cancer	0.000187	0.00183	CcSEcCtD
Chlorpromazine—ABCB1—head—skin cancer	0.000177	0.00147	CbGeAlD
Chlorpromazine—Dizziness—Docetaxel—skin cancer	0.000168	0.00164	CcSEcCtD
Chlorpromazine—ABCB1—lymph node—skin cancer	0.000124	0.00103	CbGeAlD
Chlorpromazine—CALM2—Innate Immune System—KRAS—skin cancer	1.07e-05	9.8e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Innate Immune System—KRAS—skin cancer	1.07e-05	9.8e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—BRAF—skin cancer	1.07e-05	9.79e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—TERT—skin cancer	1.07e-05	9.76e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—BRAF—skin cancer	1.06e-05	9.74e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—BRAF—skin cancer	1.06e-05	9.74e-05	CbGpPWpGaD
Chlorpromazine—ALB—Hemostasis—KRAS—skin cancer	1.06e-05	9.73e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Adaptive Immune System—KRAS—skin cancer	1.06e-05	9.73e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Hemostasis—TP53—skin cancer	1.06e-05	9.68e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Hemostasis—TP53—skin cancer	1.06e-05	9.68e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Hemostasis—HRAS—skin cancer	1.04e-05	9.57e-05	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling by GPCR—IL6—skin cancer	1.03e-05	9.46e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.03e-05	9.44e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Adaptive Immune System—KRAS—skin cancer	1.03e-05	9.41e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Adaptive Immune System—KRAS—skin cancer	1.03e-05	9.41e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.02e-05	9.37e-05	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling Pathways—KRAS—skin cancer	1.02e-05	9.31e-05	CbGpPWpGaD
Chlorpromazine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.01e-05	9.26e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Hemostasis—HRAS—skin cancer	1.01e-05	9.25e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Hemostasis—HRAS—skin cancer	1.01e-05	9.25e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling by GPCR—NRAS—skin cancer	1e-05	9.19e-05	CbGpPWpGaD
Chlorpromazine—CYP3A4—Metabolism—ENO2—skin cancer	9.97e-06	9.13e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling by GPCR—NRAS—skin cancer	9.86e-06	9.04e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling by GPCR—IL6—skin cancer	9.86e-06	9.04e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling by GPCR—NRAS—skin cancer	9.84e-06	9.02e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling by GPCR—KRAS—skin cancer	9.83e-06	9.01e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling by GPCR—NRAS—skin cancer	9.81e-06	8.99e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling by GPCR—NRAS—skin cancer	9.78e-06	8.96e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling by GPCR—KRAS—skin cancer	9.78e-06	8.96e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—TERT—skin cancer	9.72e-06	8.91e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling by GPCR—HRAS—skin cancer	9.71e-06	8.9e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling by GPCR—NRAS—skin cancer	9.69e-06	8.88e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	9.66e-06	8.85e-05	CbGpPWpGaD
Chlorpromazine—SLC22A1—Metabolism—PTGS2—skin cancer	9.61e-06	8.81e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling by GPCR—HRAS—skin cancer	9.59e-06	8.78e-05	CbGpPWpGaD
Chlorpromazine—ALB—Hemostasis—TP53—skin cancer	9.44e-06	8.65e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—BRAF—skin cancer	9.42e-06	8.64e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—TERT—skin cancer	9.4e-06	8.62e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—TERT—skin cancer	9.4e-06	8.62e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Innate Immune System—HRAS—skin cancer	9.4e-06	8.61e-05	CbGpPWpGaD
Chlorpromazine—ABCB1—Metabolism—ERCC2—skin cancer	9.4e-06	8.61e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	9.36e-06	8.58e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling by GPCR—IL6—skin cancer	9.3e-06	8.52e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—BRAF—skin cancer	9.27e-06	8.5e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—BRAF—skin cancer	9.25e-06	8.48e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—BRAF—skin cancer	9.22e-06	8.45e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—BRAF—skin cancer	9.19e-06	8.43e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling by GPCR—IL6—skin cancer	9.17e-06	8.41e-05	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—NRAS—skin cancer	9.11e-06	8.35e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—BRAF—skin cancer	9.1e-06	8.34e-05	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—NRAS—skin cancer	9.1e-06	8.34e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Innate Immune System—HRAS—skin cancer	9.09e-06	8.33e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Innate Immune System—HRAS—skin cancer	9.09e-06	8.33e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—BRAF—skin cancer	9.08e-06	8.32e-05	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling Pathways—TP53—skin cancer	9.03e-06	8.28e-05	CbGpPWpGaD
Chlorpromazine—ALB—Hemostasis—HRAS—skin cancer	9.03e-06	8.27e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Adaptive Immune System—HRAS—skin cancer	9.02e-06	8.27e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Innate Immune System—IL6—skin cancer	8.99e-06	8.24e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	8.97e-06	8.22e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Metabolism—PTGS2—skin cancer	8.88e-06	8.14e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Disease—PTGS2—skin cancer	8.88e-06	8.14e-05	CbGpPWpGaD
Chlorpromazine—CYP2D6—Metabolism—ERCC2—skin cancer	8.86e-06	8.12e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Adaptive Immune System—HRAS—skin cancer	8.73e-06	8e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Adaptive Immune System—HRAS—skin cancer	8.73e-06	8e-05	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—NRAS—skin cancer	8.71e-06	7.99e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Innate Immune System—IL6—skin cancer	8.7e-06	7.97e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Innate Immune System—IL6—skin cancer	8.7e-06	7.97e-05	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling Pathways—HRAS—skin cancer	8.64e-06	7.92e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling by GPCR—KRAS—skin cancer	8.63e-06	7.91e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—PTGS2—skin cancer	8.59e-06	7.87e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—PTGS2—skin cancer	8.59e-06	7.87e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling by GPCR—KRAS—skin cancer	8.49e-06	7.78e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling by GPCR—KRAS—skin cancer	8.47e-06	7.76e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling by GPCR—KRAS—skin cancer	8.45e-06	7.74e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—BRAF—skin cancer	8.44e-06	7.73e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling by GPCR—KRAS—skin cancer	8.42e-06	7.71e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling by GPCR—HRAS—skin cancer	8.35e-06	7.66e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling by GPCR—KRAS—skin cancer	8.34e-06	7.64e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—NRAS—skin cancer	8.32e-06	7.62e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	8.31e-06	7.62e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling by GPCR—HRAS—skin cancer	8.31e-06	7.62e-05	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling Pathways—IL6—skin cancer	8.27e-06	7.58e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by GPCR—NRAS—skin cancer	8.19e-06	7.5e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Metabolism—PTGS2—skin cancer	8.15e-06	7.47e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling by GPCR—IL6—skin cancer	8e-06	7.33e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	7.96e-06	7.29e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling by GPCR—IL6—skin cancer	7.95e-06	7.29e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by GPCR—NRAS—skin cancer	7.92e-06	7.26e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by GPCR—NRAS—skin cancer	7.92e-06	7.26e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—NRAS—skin cancer	7.84e-06	7.19e-05	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—KRAS—skin cancer	7.84e-06	7.19e-05	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—KRAS—skin cancer	7.83e-06	7.18e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—NRAS—skin cancer	7.74e-06	7.09e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	7.72e-06	7.08e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—BRAF—skin cancer	7.7e-06	7.05e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling by GPCR—IL6—skin cancer	7.61e-06	6.98e-05	CbGpPWpGaD
Chlorpromazine—CYP1A2—Metabolism—ERCC2—skin cancer	7.5e-06	6.88e-05	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—KRAS—skin cancer	7.5e-06	6.87e-05	CbGpPWpGaD
Chlorpromazine—CYP2E1—Metabolism—PTGS2—skin cancer	7.48e-06	6.86e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Immune System—NRAS—skin cancer	7.48e-06	6.86e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—BRAF—skin cancer	7.45e-06	6.82e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—BRAF—skin cancer	7.45e-06	6.82e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Metabolism—PTGS2—skin cancer	7.44e-06	6.81e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling by GPCR—HRAS—skin cancer	7.33e-06	6.72e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Immune System—NRAS—skin cancer	7.24e-06	6.63e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Immune System—NRAS—skin cancer	7.24e-06	6.63e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling by GPCR—HRAS—skin cancer	7.22e-06	6.61e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling by GPCR—HRAS—skin cancer	7.2e-06	6.6e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Metabolism—PTGS2—skin cancer	7.19e-06	6.59e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Metabolism—PTGS2—skin cancer	7.19e-06	6.59e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling by GPCR—HRAS—skin cancer	7.18e-06	6.58e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—KRAS—skin cancer	7.16e-06	6.56e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling by GPCR—HRAS—skin cancer	7.16e-06	6.56e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling by GPCR—HRAS—skin cancer	7.09e-06	6.49e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	7.07e-06	6.48e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by GPCR—KRAS—skin cancer	7.05e-06	6.46e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling by GPCR—IL6—skin cancer	7.02e-06	6.43e-05	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—TP53—skin cancer	6.97e-06	6.39e-05	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—TP53—skin cancer	6.96e-06	6.38e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Disease—NRAS—skin cancer	6.91e-06	6.33e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling by GPCR—IL6—skin cancer	6.91e-06	6.33e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling by GPCR—IL6—skin cancer	6.89e-06	6.32e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling by GPCR—IL6—skin cancer	6.87e-06	6.3e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling by GPCR—IL6—skin cancer	6.85e-06	6.28e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by GPCR—KRAS—skin cancer	6.82e-06	6.25e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by GPCR—KRAS—skin cancer	6.82e-06	6.25e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling by GPCR—IL6—skin cancer	6.78e-06	6.22e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling by GPCR—IL6—skin cancer	6.76e-06	6.2e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—KRAS—skin cancer	6.75e-06	6.19e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—NRAS—skin cancer	6.75e-06	6.18e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—NRAS—skin cancer	6.71e-06	6.15e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—NRAS—skin cancer	6.68e-06	6.12e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—NRAS—skin cancer	6.68e-06	6.12e-05	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—HRAS—skin cancer	6.67e-06	6.11e-05	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—TP53—skin cancer	6.67e-06	6.11e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—KRAS—skin cancer	6.66e-06	6.1e-05	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—HRAS—skin cancer	6.66e-06	6.1e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	6.57e-06	6.02e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Immune System—KRAS—skin cancer	6.44e-06	5.9e-05	CbGpPWpGaD
Chlorpromazine—ALB—Metabolism—PTGS2—skin cancer	6.43e-06	5.89e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—NRAS—skin cancer	6.42e-06	5.89e-05	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—IL6—skin cancer	6.38e-06	5.85e-05	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—HRAS—skin cancer	6.37e-06	5.84e-05	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—IL6—skin cancer	6.37e-06	5.84e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—TP53—skin cancer	6.36e-06	5.83e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling by GPCR—IL6—skin cancer	6.28e-06	5.76e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Immune System—KRAS—skin cancer	6.23e-06	5.71e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Immune System—KRAS—skin cancer	6.23e-06	5.71e-05	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—IL6—skin cancer	6.1e-06	5.59e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—HRAS—skin cancer	6.09e-06	5.58e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—TP53—skin cancer	6e-06	5.5e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by GPCR—HRAS—skin cancer	5.99e-06	5.49e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Disease—KRAS—skin cancer	5.95e-06	5.45e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—NRAS—skin cancer	5.92e-06	5.43e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—TP53—skin cancer	5.92e-06	5.43e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—NRAS—skin cancer	5.83e-06	5.34e-05	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—IL6—skin cancer	5.82e-06	5.34e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—NRAS—skin cancer	5.81e-06	5.33e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—KRAS—skin cancer	5.81e-06	5.32e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—NRAS—skin cancer	5.8e-06	5.31e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by GPCR—HRAS—skin cancer	5.8e-06	5.31e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by GPCR—HRAS—skin cancer	5.8e-06	5.31e-05	CbGpPWpGaD
Chlorpromazine—CYP3A4—Metabolism—ERCC2—skin cancer	5.79e-06	5.31e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—NRAS—skin cancer	5.78e-06	5.29e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—KRAS—skin cancer	5.78e-06	5.29e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—KRAS—skin cancer	5.75e-06	5.27e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—KRAS—skin cancer	5.75e-06	5.27e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—HRAS—skin cancer	5.74e-06	5.26e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by GPCR—IL6—skin cancer	5.73e-06	5.25e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—NRAS—skin cancer	5.72e-06	5.24e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—NRAS—skin cancer	5.71e-06	5.23e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—HRAS—skin cancer	5.66e-06	5.19e-05	CbGpPWpGaD
Chlorpromazine—ABCB1—Metabolism—PTGS2—skin cancer	5.64e-06	5.16e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by GPCR—IL6—skin cancer	5.55e-06	5.08e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by GPCR—IL6—skin cancer	5.55e-06	5.08e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—KRAS—skin cancer	5.53e-06	5.07e-05	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—IL6—skin cancer	5.49e-06	5.03e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Immune System—HRAS—skin cancer	5.47e-06	5.02e-05	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—IL6—skin cancer	5.42e-06	4.97e-05	CbGpPWpGaD
Chlorpromazine—CYP2D6—Metabolism—PTGS2—skin cancer	5.31e-06	4.87e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—NRAS—skin cancer	5.3e-06	4.86e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Immune System—HRAS—skin cancer	5.3e-06	4.85e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Immune System—HRAS—skin cancer	5.3e-06	4.85e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Immune System—IL6—skin cancer	5.24e-06	4.8e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—TP53—skin cancer	5.16e-06	4.73e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—TP53—skin cancer	5.13e-06	4.7e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—KRAS—skin cancer	5.1e-06	4.67e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Immune System—IL6—skin cancer	5.07e-06	4.64e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Immune System—IL6—skin cancer	5.07e-06	4.64e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Disease—HRAS—skin cancer	5.05e-06	4.63e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—KRAS—skin cancer	5.02e-06	4.6e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—KRAS—skin cancer	5e-06	4.59e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—KRAS—skin cancer	4.99e-06	4.57e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—KRAS—skin cancer	4.97e-06	4.56e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—HRAS—skin cancer	4.93e-06	4.52e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—KRAS—skin cancer	4.92e-06	4.51e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—TP53—skin cancer	4.91e-06	4.5e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—KRAS—skin cancer	4.91e-06	4.5e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—HRAS—skin cancer	4.91e-06	4.5e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—HRAS—skin cancer	4.89e-06	4.48e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—HRAS—skin cancer	4.89e-06	4.48e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—NRAS—skin cancer	4.84e-06	4.43e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Disease—IL6—skin cancer	4.84e-06	4.43e-05	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—IL6—skin cancer	4.72e-06	4.33e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—HRAS—skin cancer	4.7e-06	4.31e-05	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—IL6—skin cancer	4.7e-06	4.31e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—NRAS—skin cancer	4.68e-06	4.29e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—NRAS—skin cancer	4.68e-06	4.29e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—IL6—skin cancer	4.68e-06	4.29e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—IL6—skin cancer	4.68e-06	4.29e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—KRAS—skin cancer	4.56e-06	4.18e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—TP53—skin cancer	4.53e-06	4.15e-05	CbGpPWpGaD
Chlorpromazine—CYP1A2—Metabolism—PTGS2—skin cancer	4.5e-06	4.12e-05	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—IL6—skin cancer	4.5e-06	4.12e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—TP53—skin cancer	4.46e-06	4.09e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—TP53—skin cancer	4.45e-06	4.08e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—TP53—skin cancer	4.43e-06	4.06e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—TP53—skin cancer	4.42e-06	4.05e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—TP53—skin cancer	4.38e-06	4.01e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—TP53—skin cancer	4.36e-06	4e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—HRAS—skin cancer	4.33e-06	3.97e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—HRAS—skin cancer	4.26e-06	3.91e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—HRAS—skin cancer	4.25e-06	3.9e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—HRAS—skin cancer	4.24e-06	3.89e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—HRAS—skin cancer	4.23e-06	3.87e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—HRAS—skin cancer	4.19e-06	3.84e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—HRAS—skin cancer	4.17e-06	3.83e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—KRAS—skin cancer	4.16e-06	3.82e-05	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—IL6—skin cancer	4.15e-06	3.8e-05	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—IL6—skin cancer	4.08e-06	3.74e-05	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—IL6—skin cancer	4.07e-06	3.73e-05	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—IL6—skin cancer	4.06e-06	3.72e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—TP53—skin cancer	4.06e-06	3.72e-05	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—IL6—skin cancer	4.05e-06	3.71e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—KRAS—skin cancer	4.03e-06	3.69e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—KRAS—skin cancer	4.03e-06	3.69e-05	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—IL6—skin cancer	4.01e-06	3.67e-05	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—IL6—skin cancer	4e-06	3.66e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—HRAS—skin cancer	3.88e-06	3.55e-05	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—IL6—skin cancer	3.71e-06	3.4e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—TP53—skin cancer	3.7e-06	3.39e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—TP53—skin cancer	3.58e-06	3.28e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—TP53—skin cancer	3.58e-06	3.28e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—HRAS—skin cancer	3.54e-06	3.24e-05	CbGpPWpGaD
Chlorpromazine—CYP3A4—Metabolism—PTGS2—skin cancer	3.47e-06	3.18e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—HRAS—skin cancer	3.42e-06	3.14e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—HRAS—skin cancer	3.42e-06	3.14e-05	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—IL6—skin cancer	3.39e-06	3.1e-05	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—IL6—skin cancer	3.28e-06	3e-05	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—IL6—skin cancer	3.28e-06	3e-05	CbGpPWpGaD
